Cargando…

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

Glulisine (Apidra(®)) is a rapid-acting human insulin analog approved for use in children with diabetes mellitus ≥4 years of age. Management of children with type 1 diabetes has seen a shift in favor of mimicking normal physiological insulin responses with multiple daily injections or continuous sub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lih, Anna, Hibbert, Emily, Wong, Tang, Girgis, Christian M, Garg, Nidhi, Carter, John N
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047962/ https://www.ncbi.nlm.nih.gov/pubmed/21437110 http://dx.doi.org/10.2147/DMSOTT.S5116

Ejemplares similares

Insulin glulisine in the management of diabetes
por: Yamada, Satoru
Publicado: (2009)

Immunologic Tolerance to the Insulin Analogue Glulisine
por: Ozaki, Nobuaki, et al.
Publicado: (2010)

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine
por: Ulrich, Heather, et al.
Publicado: (2007)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2015)

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
por: Seufert, Jochen, et al.
Publicado: (2021)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Gillis, Richard B., et al.
Publicado: (2021)

Insulin Glulisine May Cause a Disease Resembling Insulin Autoimmune Syndrome: Case Report
por: Kawasaki, Maki, et al.
Publicado: (2013)

Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
por: Bergenstal, Richard M., et al.
Publicado: (2008)

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes
por: Bolli, G B, et al.
Publicado: (2011)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
por: Pfohl, Martin, et al.
Publicado: (2021)

Glulisine Versus Human Regular Insulin in Combination With Glargine in Noncritically Ill Hospitalized Patients With Type 2 Diabetes: A randomized double-blind study
por: Meyer, Christian, et al.
Publicado: (2010)

A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
por: Baldwin, David, et al.
Publicado: (2012)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
por: Hidvégi, Tibor, et al.
Publicado: (2020)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes
por: Kawaguchi, Yuji, et al.
Publicado: (2021)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
por: Owens, D R, et al.
Publicado: (2011)

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
por: Deepaklal, M.C., et al.
Publicado: (2014)

Can Fetuin-A Be a Marker for Insulin Resistance and Poor Glycemic Control in Children with Type 1 Diabetes Mellitus?
por: Şiraz, Ülkü Gül, et al.
Publicado: (2017)

Insulin combined with Chinese medicine improves glycemic outcome through multiple pathways in patients with type 2 diabetes mellitus
por: Zhang, Xinxia, et al.
Publicado: (2015)

Significance of Glycemic Variability in Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2021)

Glycemic Control in Kenyan Children and Adolescents with Type 1 Diabetes Mellitus
por: Ngwiri, Thomas, et al.
Publicado: (2015)

Brewer's Yeast Improves Glycemic Indices in Type 2 Diabetes Mellitus
por: Hosseinzadeh, Payam, et al.
Publicado: (2013)

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus
por: Chien, Ming‐Nan, et al.
Publicado: (2016)

Reconsidering the Basal Proportion of Insulin Dose: Glycemic and Microvascular Outcomes in Type 1 Diabetes Mellitus
por: Pozos-Varela, Francisco Javier, et al.
Publicado: (2021)

Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Detemir plus aspart and glulisine induced lipoatrophy: 2015 literature review and report of a new case
por: Saberi, Sima, et al.
Publicado: (2015)

Predictors of glycemic control in children with Type 1 diabetes mellitus in Assiut-Egypt
por: Mohammad, Hanaa A., et al.
Publicado: (2012)

Glycemic Control in Children and Youth With Type 1 Diabetes Mellitus in Saudi Arabia
por: Al Zahrani, Abdullah M, et al.
Publicado: (2019)

Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
por: Toi, Norikazu, et al.
Publicado: (2018)

Glycemic control and treatment satisfaction in Saudi diabetic children on insulin pump therapy
por: Bin-Abbas, Bassam S., et al.
Publicado: (2006)

Glycemic control and treatment satisfaction in Saudi diabetic children on insulin pump therapy
por: Bin-Abbas, Bassam S., et al.
Publicado: (2006)

Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants
por: Radojkovic, Jana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gms995muv20k41cgbv5mg7mrsq